Sociedad Americana de Hirudoterapia

Medicines and Healthcare products Regulatory Agency

MHRA · United Kingdom · europe

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Post-Brexit UK regulator — accepts EU CE marks during transition, with UKCA marking now phased in for Great Britain (Northern Ireland follows EU MDR via Windsor Framework).

Regulatory Profile

Agency type
national regulator
Region
europe
Country
United Kingdom
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Medical Devices Regulations 2002 (SI 2002/618), as amended
  • Medicines and Medical Devices Act 2021
  • UKCA mark from 1 July 2024 (with CE recognition extended indefinitely for GB market under 2024 amendment SI)

Prescriber Requirements

  • Prescription medical device — supplied on order of a GMC-registered doctor, NMC-registered nurse prescriber, GPhC-registered pharmacist independent prescriber, or HCPC-registered podiatrist within scope
  • NHS application typically by tissue viability nurse under standing order; plastic-surgery indications by registered nurse on consultant ward

Supply Chain & GMP

Manufacturer / UK Responsible Person must register devices with MHRA via Device Online Registration System (DORS). GMP-equivalent traceability per ISO 13485. English labelling mandatory; cold chain 4–10 °C.

Import/Export Rules

Import to GB requires MHRA registration; Northern Ireland follows EU MDR under Windsor Framework. CITES Appendix II permit issued by UK CITES Management Authority (APHA). Live-invertebrate import additionally requires APHA veterinary clearance.

Reimbursement Context

NHS England Specialised Commissioning covers leech therapy under reconstructive-surgery service specifications (NHS England 13X05). NICE has not issued a Technology Appraisal — clinical practice guided by BAPRAS consensus.

ASH Editorial Notes

Biopharm Leeches (Hendy, Wales) is the principal UK breeder and a globally significant supplier; supplies NHS plastic-surgery units and exports to FDA-regulated US market via Ricarimpex-parallel pathway.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.